| Literature DB >> 35011754 |
Soledad Jimenez-Carmona1, Pedro Alemany-Marquez1, Pablo Alvarez-Ramos1, Eduardo Mayoral2, Manuel Aguilar-Diosdado3.
Abstract
BACKGROUND: Retinopathy is the most common microvascular complication of diabetes mellitus. It is the leading cause of blindness among working-aged people in developed countries. The use of telemedicine in the screening system has enabled the application of large-scale population-based programs for early retinopathy detection in diabetic patients. However, the need to support ophthalmologists with other trained personnel remains a barrier to broadening its implementation.Entities:
Keywords: diabetic retinopathy; diagnostic accuracy; population-based screening; sight-threatening diabetic retinopathy; teleophthalmology
Year: 2021 PMID: 35011754 PMCID: PMC8745311 DOI: 10.3390/jcm11010014
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Software analysis 2iRetinex: (a) A original APDR image of fundus photography of a patient with diabetic retinopathy; (b) Location and type of lesions. Superimposed the coordinates system. Red lesions in red, white lesions in blue.
Main characteristics of the study sample obtained from de APDR between April 2017 and June 2018. * Mean SD. DR = diabetic retinopathy. DME = diabetic macular edema. NDME = no diabetic macular edema. STDR = sight-threatening DR.
| Variable of Interest | Study Sample ( | |||
|---|---|---|---|---|
| Gender (F/M) | 43.9%/56.1% (1545/1975) | |||
| Age (years) | 64.4 ± 14.6 * | |||
| Years from diagnosis | 10.4 ± 7.5 * | |||
| Mydriasis (before photograph) | 97.8% | (3443) | ||
| Diabetes type | Type 2 | 88.2% | (3103) | |
| Type 1 | 11.4% | (402) | ||
| Others | 0.4% | (15) | ||
| Ungradable images (UNG) | 11.6% | (407) | ||
| No diabetic Retinopathy (NODR) | 69.9% | (2460) | ||
| Diabetic retinopathy (DR) | Mild | 8.1% | (286) | |
| Moderate | NDME | 8.1% | (285) | |
| DME | 1.8% | (65) | ||
| Severe | NDME | 0.1% | (2) | |
| DME | 0.2% | (8) | ||
| Proliferative | NDME | 0.1% | (3) | |
| DME | 0.1% | (4) | ||
| STDR | 2.3% | (82) | ||
Comparison of the study variables between female and male patients. DR = diabetic retinopathy. DME = macular edema diabetic. STDR = sight-threatening DR. * Results with statistically significant differences.
| Variable of Interest | Female ( | Male ( | ||
|---|---|---|---|---|
| Age (years) | 65.4 ± 15.6 | 64 ± 13.8 | 0.0419 * | |
| Years from diagnosis | 11.1 ± 8.1 | 9.8 ± 7 | <0.0001 * | |
| Mydriasis | 97.6% | 98% | 0.4196 | |
| Diabetes type | Type 2 | 85.8% | 90% | =0.0001 * |
| Type 1 | 13.7% | 9.6% | =0.0001 * | |
| Others | 0.5% | 0.4% | 0.6579 | |
| DR stage | Mild | 8.1% | 8.2% | 0.9143 |
| Moderate | 10% | 9.9% | 0.9216 | |
| Severe | 0.2% | 0.4% | 0.2913 | |
| Proliferative | 0.2% | 0.2% | 1 | |
| DME | 2.1% | 2.2% | 0.8394 | |
| STDR | 2.2% | 2.4% | 0.6952 | |
Comparison of the common variables between patients with gradable and ungradable images. * Results with statistically significant differences.
| Variable of Interest | Gradable | Ungradable | ||
|---|---|---|---|---|
| Gender (F/M) | 43.8%/56.2% | 44.2%/55.8% | 0.8785 | |
| Age (years) | 63.4 ± 14.6 | 72.6 ± 11.8 | <0.0001 * | |
| Years from diagnosis | 10.3 ± 7.3 | 10.9 ± 9.2 | 0.1450 | |
| Mydriasis | 98% | 96.6% | 0.0678 | |
| Diabetes type | Type 2 | 87.2% | 95.6% | <0.0001 * |
| Type 1 | 12.4% | 4.2% | <0.0001 * | |
| Others | 0.4% | 0% | 0.2012 | |
Number of patients in every pair of diagnostic categories comparing ALG vs. OPH.
| OPH-DR | OPH-NODR | OPH-UNG | Total | |
|---|---|---|---|---|
| ALG-DR | 455 | 379 | 33 | 867 |
| ALG-NODR | 80 | 1582 | 64 | 1726 |
| ALG-UNG | 118 | 499 | 310 | 927 |
| Total | 653 | 2460 | 407 | 3520 |
Number of patients in every pair of diagnostic categories comparing PCP vs. OPH.
| OPH-DR | OPH-NODR | OPH-UNG | Total | |
|---|---|---|---|---|
| PCP-DR | 373 | 233 | 25 | 631 |
| PCP-NODR | 214 | 2005 | 209 | 2428 |
| PCP-UNG | 66 | 222 | 173 | 461 |
| Total | 653 | 2460 | 407 | 3520 |
Comparison of the study variables ALG-OPH vs. PCP-OPH. NDME = no diabetic macular edema. DR = diabetic retinopathy. DME = diabetic macular edema. STDR = sight-threatening DR. * Results with statistically significant differences.
| Variable of Interest | ALG-OPH ( | PCP-OPH ( | ||||
|---|---|---|---|---|---|---|
| Gender (F/M) | 42.9%/57.1% | 43.6%/56.4% | 0.6071 | |||
| Age (years) | 61.4 ± 14.7 | 62.8 ± 14.6 | 0.0003 * | |||
| Years from diagnosis | 10.2 ± 7.3 | 10.3 ± 7.3 | 0.6522 | |||
| Mydriasis | 98.3% (2454) | 98.6% (2785) | 0.3753 | |||
| Diabetes type | Type 1 | 14.5% (361) | 12.8% (362) | 0.0710 | ||
| Type 2 | 85.2% (2126) | 86.8% (2451) | 0.0928 | |||
| Others | 0.3% (9) | 0.4% (12) | 0.5394 | |||
| NODR | 78.6% (1961) | 79.2% (2238) | 0.5924 | |||
| DR | 21.43% (535) | 20.78 (587) | 0.5619 | |||
| DR stage | Mild | 10.1% (251) | 9.5% (267) | 0.4622 | ||
| Moderate | 10.9% (272) | (NDME 217) | 10.8% (305) | (NDME 245) | 0.9068 | |
| (DME 55) | (DME 60) | |||||
| Severe | 0.3% (7) | (NDME 1) | 0.3% (9) | (NDME 2) | 1 | |
| (DME 6) | (DME 7) | |||||
| Proliferative | 0.2% (5) | (NDME 2) | 0.2% (6) | (NDME 2) | 1 | |
| (DME 3) | (DME 4) | |||||
| DME | 2.6% (64) | 2.5% (71) | 0.8173 | |||
| STDR | 2.7% (67) | 2.7% (75) | 1 | |||
Unpaired sample. Diagnostic category pairs frequency and diagnostic validity indexes.
| Variable of Interest | ALG-OPH (95% CI) | PCP-OPH (95% CI) |
|---|---|---|
| True Positive | 455 | 373 |
| False Positive | 379 | 233 |
| False Negative | 80 | 214 |
| True Negative | 1582 | 2005 |
| Prevalence | 21.43% (19.80−23.06) | 20.78% (19.26−22.29) |
| Sensitivity | 85.05% (81.93−88.16) | 63.54% (59.56−67.52) |
| Specificity | 80.67% (78.90−82.45) | 89.59% (88.30−90.88) |
| Positive Predictive Value | 54.56% (51.12−58.00) | 61.55% 57.60−65.51) |
| Negative Predictive Value | 95.19% (94.13−96.25) | 90.36% (89.11−91.61) |
| Likelihood Ratio + | 4.40 (3.99−4.85) | 6.10 (5.33−6.99) |
| Likelihood Ratio - | 0.19 (0.15−0.23) | 0.41 (0.37−0.45) |
Ranges of likelihood ratio values and their impact on diagnostic accuracy.
| Likelihood Ratio + | Likelihood Ratio − | Usefulness |
|---|---|---|
| 10 | <0.1 | Highly relevant |
| 5–10 | 5–10 | Good |
| 2–5 | 2–5 | Fair |
| <2 | <2 | Poor |
Figure 2ROC curves comparison. Green line: Algorithm. Red line: Primary Care Physician.
Main descriptors of the sample obtained from de APDR for the study between April 2017 and June 2018. * Mean SD. DME = diabetic macular edema. NDME = macular edema non-diabetic. STDR= sight-threatening DR.
| Variable of Interest | Study Sample ( | ||
|---|---|---|---|
| Gender (F/M) | 42.7%/57.3% (997/1338) | ||
| Age (years) | 61.1 ± 14.7 * | ||
| Years from diagnosis | 10.1 ± 7.2 * | ||
| Mydriasis (before photograph) | 98.8% (2306) | ||
| Diabetes type | Type 2 | 85% (1984) | |
| Type 1 | 14.7% (343) | ||
| Others | 0.3% (8) | ||
| No Diabetic Retinopathy (NODR) | 78.9% (1842) | ||
| DR prevalence | 21.1% | ||
| Diabetic retinopathy (DR) | Mild | 10.2% (238) | |
| Moderate | NDME | 8.3% (194) | |
| DME | 2.2% (51) | ||
| Severe | NDME | 0.04% (1) | |
| DME | 0.2% (5) | ||
| Proliferative | NDME | 0.04% (1) | |
| DME | 0.1% (3) | ||
| STDR | 2.6% (61) | ||
Paired sample. Diagnostic category pairs frequency and diagnostic validity indexes.
| Variable of Interest | ALG-OPH (95% CI) | PCP-OPH (95% CI) |
|---|---|---|
| True Positive | 418 | 300 |
| False Positive | 351 | 200 |
| False Negative | 75 | 193 |
| True Negative | 1491 | 1642 |
| Prevalence | 21.1% (19.44−22.79) | |
| Sensibility | 84.8% (81.52−88.06) | 60.9% (56.44−65.26) |
| Specificity | 80.9% (79.12−82.77) | 89.1% (87.69−90.59) |
| Positive Predictive Value | 54.36% (50.77−57.94) | 60% (55.61−64.39) |
| Negative Predictive Value | 95.21% (94.12−96.30) | 89.48% (88.05−90.91) |
| Likelihood Ratio + | 4.45 (4.02−4.92) | 5.60 (4.83−6.50) |
| Likelihood Ratio − | 0.19 (0.15−0.23) | 0.44 (0.39−0.49) |
Figure 3ROC curves comparison of the diagnostic validity. Paired sample. Red: Algorithm. Green: Primary Care Physician.